Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Pharmaceutical company Merck KGaA, Darmstadt, Germany brings new cancer drugs on the market

Avelumab is the new antibody with which Germany’s Merck KGaA, Darmstadt, Germany wants to fight cancer. It would strengthen the body's immune system to fight cancer cells. While cancer immunotherapy as a treatment method is still in its infancy, it is considered to be promising. Although Avelumab is still not on the market, Merck KGgaA, Darmstadt, Germany can hope for accelerated approval in the US. The US Food and Drug Administration has given the antibody a “fast-track” status for the treatment of metastatic Merkel cell carcinoma, a rare, malignant skin tumor. A “fast-track” status speeds up the review of drugs that treat serious diseases with a high unmet medical need.
Merck KGaA, Darmstadt, Germany's collaboration with Pfizer
While Merck KGaA, Darmstadt, Germany has several clinical trials in various types of cancer with Avelumab, for the treatment of Merkel cell carcinoma, the antibody is in the second of three phases of clinical development. The company discovered the antibody on its own almost ten years ago and tested its effectiveness in various studies. However, in 2014, Merck KGaA, Darmstadt, Germany entered an alliance with US pharmaceutical giant Pfizer to develop and co-promote Avelumab. Merck KGaA, Darmstadt, Germany expects the first launch of Avelumab in 2017 and then achieve at least one further marketing authorization per year by 2022.

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.